AU2018244442A1

AU2018244442A1 - Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same

Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same Download PDF

Info

Publication number: AU2018244442A1
Authority: AU; Australia
Prior art keywords: indirubin; solvent; dihydro; derivative; benzazepin
Prior art date: 2017-03-29
Legal status : Abandoned

Application number

AU2018244442A

Other languages

English (en)

Inventor

Paul Boucher

Bin Wu

Current Assignee

Cytodigm Inc

Original Assignee

Cytodigm Inc

Priority date

2017-03-29

Filing date

2018-03-29

Publication date

2019-10-24

2018-03-29 Application filed by Cytodigm Inc filed Critical Cytodigm Inc

2019-10-24 Publication of AU2018244442A1 publication Critical patent/AU2018244442A1/en

2023-07-13 Assigned to CYTODIGM, INC. reassignment CYTODIGM, INC. Request for Assignment Assignors: PHOSPHOREX, INC.

Status Abandoned legal-status Critical Current

Links

CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 title claims abstract description 357
CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 title claims abstract description 154
CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 title claims abstract description 154
238000000034 method Methods 0.000 title claims description 97
239000008194 pharmaceutical composition Substances 0.000 title claims description 39
239000000203 mixture Substances 0.000 claims abstract description 49
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
239000002904 solvent Substances 0.000 claims description 126
229920000642 polymer Polymers 0.000 claims description 61
239000002245 particle Substances 0.000 claims description 44
239000008186 active pharmaceutical agent Substances 0.000 claims description 43
239000000243 solution Substances 0.000 claims description 39
-1 poly(ethylene glycol) Polymers 0.000 claims description 31
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 28
239000000839 emulsion Substances 0.000 claims description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000003381 stabilizer Substances 0.000 claims description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 18
238000009472 formulation Methods 0.000 claims description 18
201000011510 cancer Diseases 0.000 claims description 17
238000004945 emulsification Methods 0.000 claims description 17
239000004094 surface-active agent Substances 0.000 claims description 16
238000003756 stirring Methods 0.000 claims description 15
229920000747 poly(lactic acid) Polymers 0.000 claims description 14
241000282414 Homo sapiens Species 0.000 claims description 13
201000004681 Psoriasis Diseases 0.000 claims description 12
239000007864 aqueous solution Substances 0.000 claims description 12
230000001804 emulsifying effect Effects 0.000 claims description 12
208000024827 Alzheimer disease Diseases 0.000 claims description 11
208000027866 inflammatory disease Diseases 0.000 claims description 11
DDLZLOKCJHBUHD-WAVHTBQISA-N 6-bromoindirubin-3'-oxime Chemical group O=C/1NC2=CC(Br)=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 claims description 10
229920001577 copolymer Polymers 0.000 claims description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 9
239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 9
238000004090 dissolution Methods 0.000 claims description 9
208000005017 glioblastoma Diseases 0.000 claims description 9
229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
238000000527 sonication Methods 0.000 claims description 8
229920001223 polyethylene glycol Polymers 0.000 claims description 7
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 6
125000000524 functional group Chemical group 0.000 claims description 6
238000000265 homogenisation Methods 0.000 claims description 6
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
208000015122 neurodegenerative disease Diseases 0.000 claims description 6
201000002528 pancreatic cancer Diseases 0.000 claims description 6
208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
239000000080 wetting agent Substances 0.000 claims description 6
208000020925 Bipolar disease Diseases 0.000 claims description 5
208000032612 Glial tumor Diseases 0.000 claims description 5
206010018338 Glioma Diseases 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
150000005829 chemical entities Chemical class 0.000 claims description 5
230000001268 conjugating effect Effects 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
238000001556 precipitation Methods 0.000 claims description 5
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 4
229920002732 Polyanhydride Polymers 0.000 claims description 4
229920001710 Polyorthoester Polymers 0.000 claims description 4
230000002159 abnormal effect Effects 0.000 claims description 4
150000001540 azides Chemical class 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
150000004985 diamines Chemical class 0.000 claims description 4
239000000975 dye Substances 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
239000007850 fluorescent dye Substances 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
208000032839 leukemia Diseases 0.000 claims description 4
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims description 4
229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 claims description 4
239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 4
229920002627 poly(phosphazenes) Polymers 0.000 claims description 4
229920001610 polycaprolactone Polymers 0.000 claims description 4
239000004632 polycaprolactone Substances 0.000 claims description 4
229920002721 polycyanoacrylate Polymers 0.000 claims description 4
229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
230000001185 psoriatic effect Effects 0.000 claims description 4
150000003573 thiols Chemical class 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 3
239000006184 cosolvent Substances 0.000 claims description 3
239000003599 detergent Substances 0.000 claims description 3
238000011026 diafiltration Methods 0.000 claims description 3
238000000502 dialysis Methods 0.000 claims description 3
239000002270 dispersing agent Substances 0.000 claims description 3
239000004088 foaming agent Substances 0.000 claims description 3
239000012535 impurity Substances 0.000 claims description 3
230000001376 precipitating effect Effects 0.000 claims description 3
206010015278 Erythrodermic psoriasis Diseases 0.000 claims description 2
206010037575 Pustular psoriasis Diseases 0.000 claims description 2
206010018797 guttate psoriasis Diseases 0.000 claims description 2
230000003902 lesion Effects 0.000 claims description 2
206010040882 skin lesion Diseases 0.000 claims description 2
231100000444 skin lesion Toxicity 0.000 claims description 2
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 27
239000002105 nanoparticle Substances 0.000 description 33
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
208000023275 Autoimmune disease Diseases 0.000 description 14
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 14
230000001363 autoimmune Effects 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
206010012601 diabetes mellitus Diseases 0.000 description 11
235000019441 ethanol Nutrition 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
102000001267 GSK3 Human genes 0.000 description 8
229920002988 biodegradable polymer Polymers 0.000 description 8
206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 8
239000000725 suspension Substances 0.000 description 8
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
208000008589 Obesity Diseases 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
201000006417 multiple sclerosis Diseases 0.000 description 7
235000020824 obesity Nutrition 0.000 description 7
150000002923 oximes Chemical class 0.000 description 7
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
206010012438 Dermatitis atopic Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
201000008937 atopic dermatitis Diseases 0.000 description 6
239000004621 biodegradable polymer Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
201000000596 systemic lupus erythematosus Diseases 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
NKRCVLNDEWURBV-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole-3-carboxamide Chemical compound C1CCCC2=C1NC=C2C(=O)N NKRCVLNDEWURBV-UHFFFAOYSA-N 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
FQCPPVRJPILDIK-UHFFFAOYSA-N chembl126077 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=CC=C21 FQCPPVRJPILDIK-UHFFFAOYSA-N 0.000 description 5
239000004005 microsphere Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
206010025323 Lymphomas Diseases 0.000 description 4
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
208000012902 Nervous system disease Diseases 0.000 description 4
201000011152 Pemphigus Diseases 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
241000700605 Viruses Species 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
208000002551 irritable bowel syndrome Diseases 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
206010007134 Candida infections Diseases 0.000 description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
206010011878 Deafness Diseases 0.000 description 3
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
206010018364 Glomerulonephritis Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
206010033645 Pancreatitis Diseases 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
XMPHNZMDLSUDQI-UHFFFAOYSA-N chembl173682 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC(Br)=CC=C4NC=3O)=NC2=C1 XMPHNZMDLSUDQI-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
XLKHCIUFNPNLIE-UHFFFAOYSA-N dnc004090 Chemical compound C12=CC(Br)=CC=C2NC2=C1CC(=O)NC1=C2SC=C1 XLKHCIUFNPNLIE-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
230000010370 hearing loss Effects 0.000 description 3
231100000888 hearing loss Toxicity 0.000 description 3
208000016354 hearing loss disease Diseases 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
MLCPSWPIYHDOKG-BUHFOSPRSA-N (3e)-3-(2-oxo-1h-indol-3-ylidene)-1h-indol-2-one Chemical compound O=C\1NC2=CC=CC=C2C/1=C1/C2=CC=CC=C2NC1=O MLCPSWPIYHDOKG-BUHFOSPRSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
XCKPUFSDEYHSKM-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole-3-carboxamide Chemical compound C1=CCC2C(C(=O)N)CNC2=C1 XCKPUFSDEYHSKM-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
229920003084 Avicel® PH-102 Polymers 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
208000027754 Endocrine autoimmune disease Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000701081 Equid alphaherpesvirus 1 Species 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 2
102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
208000024869 Goodpasture syndrome Diseases 0.000 description 2
208000003807 Graves Disease Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
208000007976 Ketosis Diseases 0.000 description 2
239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
206010030216 Oesophagitis Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
241000721454 Pemphigus Species 0.000 description 2
208000031845 Pernicious anaemia Diseases 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
208000018359 Systemic autoimmune disease Diseases 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
206010047642 Vitiligo Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
206010000496 acne Diseases 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Chemical class 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
208000037896 autoimmune cutaneous disease Diseases 0.000 description 2
201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000008468 bone growth Effects 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
201000003984 candidiasis Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
208000013677 cerebrovascular dementia Diseases 0.000 description 2
AOHZJKSTSDMBIZ-UHFFFAOYSA-N chembl111433 Chemical compound C1=CC=C2C(=O)C(C3=C(O)NC4=CC=C(C=C43)C)=NC2=C1 AOHZJKSTSDMBIZ-UHFFFAOYSA-N 0.000 description 2
IGVYXSVOVAENJU-UHFFFAOYSA-N chembl118406 Chemical compound C12=CC(C)=CC=C2NC2=C1CC(=O)NC1=C2SC=C1 IGVYXSVOVAENJU-UHFFFAOYSA-N 0.000 description 2
SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000039 congener Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
208000006881 esophagitis Diseases 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000005243 fluidization Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
208000037824 growth disorder Diseases 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
229960001507 ibrutinib Drugs 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
230000003780 keratinization Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
229960001021 lactose monohydrate Drugs 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
239000002417 nutraceutical Substances 0.000 description 2
235000021436 nutraceutical agent Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
201000005737 orchitis Diseases 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
201000001976 pemphigus vulgaris Diseases 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
201000006292 polyarteritis nodosa Diseases 0.000 description 2
229940068917 polyethylene glycols Drugs 0.000 description 2
208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
235000013772 propylene glycol Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013269 sustained drug release Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
238000005406 washing Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
QNOCRUSVMMAKSC-CCEZHUSRSA-N (3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one Chemical compound C12=CC=CC=C2N(C)C(=O)\C1=C\1C2=CC=CC=C2NC/1=O QNOCRUSVMMAKSC-CCEZHUSRSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000005999 2-bromoethyl group Chemical group 0.000 description 1
DWLMLPCWSGBXMZ-UHFFFAOYSA-N 3,4-bis(1-methylindol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(C)C=2)C(=O)NC1=O DWLMLPCWSGBXMZ-UHFFFAOYSA-N 0.000 description 1
JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 1
UQHKJRCFSLMWIA-UHFFFAOYSA-N 3-[1-(3-aminopropyl)-1h-indol-3-yl]-4-(1-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCN)C=2)C(=O)NC1=O UQHKJRCFSLMWIA-UHFFFAOYSA-N 0.000 description 1
DHDDXXFHXNXXKS-UHFFFAOYSA-N 3-[1-(3-aminopropyl)indol-3-yl]-4-(1-methyl-5-propoxyindol-3-yl)pyrrole-2,5-dione Chemical compound C1=CC=C2C(C3=C(C(NC3=O)=O)C3=CN(C)C4=CC=C(C=C43)OCCC)=CN(CCCN)C2=C1 DHDDXXFHXNXXKS-UHFFFAOYSA-N 0.000 description 1
PKYRLHZGZYKIII-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole-3-carboxylic acid Chemical compound C1CCCC2=C1NC=C2C(=O)O PKYRLHZGZYKIII-UHFFFAOYSA-N 0.000 description 1
TWOSIFOFWWXXIG-PTGBLXJZSA-N 4-[(E)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxybutane-1,2-diol Chemical compound OCC(O)CCO\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2ccccc12 TWOSIFOFWWXXIG-PTGBLXJZSA-N 0.000 description 1
UDYICULAWWRDJS-UHFFFAOYSA-N 4-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]butanamide Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCC(N)=O)C=2)C(=O)NC1=O UDYICULAWWRDJS-UHFFFAOYSA-N 0.000 description 1
PJIDEZGELMTZHM-UHFFFAOYSA-N 4-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]butanenitrile Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCC#N)C=2)C(=O)NC1=O PJIDEZGELMTZHM-UHFFFAOYSA-N 0.000 description 1
MLLBMFWDVRVGHV-UHFFFAOYSA-N 4-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]butanoic acid Chemical compound C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCC(O)=O)C=2)C(=O)NC1=O MLLBMFWDVRVGHV-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
MEHCHNDXXHCHGS-UHFFFAOYSA-N 5-bromo-2-(2-oxo-1h-indol-3-ylidene)-1h-indol-3-one Chemical compound O=C1NC2=CC=CC=C2C1=C1NC2=CC=C(Br)C=C2C1=O MEHCHNDXXHCHGS-UHFFFAOYSA-N 0.000 description 1
BUPAMFGRFQGRCA-UHFFFAOYSA-N 6-Bromoindirubin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=C(Br)C=C2NC1=O BUPAMFGRFQGRCA-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
206010002412 Angiocentric lymphomas Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010053555 Arthritis bacterial Diseases 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
208000002017 Autoimmune Hypophysitis Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010064539 Autoimmune myocarditis Diseases 0.000 description 1
208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
230000005653 Brownian motion process Effects 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108091007914 CDKs Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
206010063094 Cerebral malaria Diseases 0.000 description 1
208000024699 Chagas disease Diseases 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
240000003890 Commiphora wightii Species 0.000 description 1
206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
208000000398 DiGeorge Syndrome Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
108010011459 Exenatide Proteins 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102100035716 Glycophorin-A Human genes 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
206010073069 Hepatic cancer Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701041 Human betaherpesvirus 7 Species 0.000 description 1
241000701027 Human herpesvirus 6 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000010159 IgA glomerulonephritis Diseases 0.000 description 1
206010021263 IgA nephropathy Diseases 0.000 description 1
244000283207 Indigofera tinctoria Species 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
206010025280 Lymphocytosis Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
201000003791 MALT lymphoma Diseases 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
206010027260 Meningitis viral Diseases 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
206010028034 Mouth ulceration Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
208000010195 Onychomycosis Diseases 0.000 description 1
208000007117 Oral Ulcer Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
208000026433 Pemphigus erythematosus Diseases 0.000 description 1
208000027086 Pemphigus foliaceus Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037765 Radiation pneumonitis Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
241001061127 Thione Species 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
102100031013 Transgelin Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
206010069351 acute lung injury Diseases 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001279 adipic acids Chemical class 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000003741 agents affecting lipid metabolism Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000883 anti-obesity agent Substances 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000003926 antimycobacterial agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000003200 antithyroid agent Substances 0.000 description 1
229940043671 antithyroid preparations Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
208000020176 autoimmune hypoparathyroidism Diseases 0.000 description 1
208000006424 autoimmune oophoritis Diseases 0.000 description 1
201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
238000005537 brownian motion Methods 0.000 description 1
239000008372 bubblegum flavor Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229940067596 butylparaben Drugs 0.000 description 1
229940014641 bydureon Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
KTNYZVYVXUQVCW-UHFFFAOYSA-N chembl173178 Chemical compound C1=CC=C2C(=O)C(C=3C=4C=C(C(=CC=4NC=3O)Br)C)=NC2=C1 KTNYZVYVXUQVCW-UHFFFAOYSA-N 0.000 description 1
WPLPQAPDKVSKJQ-UHFFFAOYSA-N chembl176904 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC=C(Br)C=C4NC=3O)=NC2=C1 WPLPQAPDKVSKJQ-UHFFFAOYSA-N 0.000 description 1
LVXRFLDTIWZWSH-UHFFFAOYSA-N chembl210446 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC=CC(F)=C4NC=3O)=NC2=C1 LVXRFLDTIWZWSH-UHFFFAOYSA-N 0.000 description 1
HQEUNYHHPDEVEG-UHFFFAOYSA-N chembl214173 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC=CC(Br)=C4NC=3O)=NC2=C1 HQEUNYHHPDEVEG-UHFFFAOYSA-N 0.000 description 1
WCCYEJYTLNWYCC-UHFFFAOYSA-N chembl337300 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=C(I)C=C21 WCCYEJYTLNWYCC-UHFFFAOYSA-N 0.000 description 1
HYMACPDEJIEMST-UHFFFAOYSA-N chembl373834 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=C(Br)C=CC=C21 HYMACPDEJIEMST-UHFFFAOYSA-N 0.000 description 1
NWTPNTSXENAZQO-UHFFFAOYSA-N chembl378191 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC=CC(Cl)=C4NC=3O)=NC2=C1 NWTPNTSXENAZQO-UHFFFAOYSA-N 0.000 description 1
OUWDTFBGCYJAMD-UHFFFAOYSA-N chembl379160 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC=CC(I)=C4NC=3O)=NC2=C1 OUWDTFBGCYJAMD-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000005056 compaction Methods 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000003602 elastase inhibitor Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
235000008524 evening primrose extract Nutrition 0.000 description 1
229940089020 evening primrose oil Drugs 0.000 description 1
239000010475 evening primrose oil Substances 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
208000033699 familial Guillain-Barre syndrome Diseases 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
235000004426 flaxseed Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
230000003325 follicular Effects 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
229940068517 fruit extracts Drugs 0.000 description 1
239000008369 fruit flavor Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
150000002238 fumaric acids Chemical class 0.000 description 1
210000001280 germinal center Anatomy 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
235000009569 green tea Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000004217 heart function Effects 0.000 description 1
208000018578 heart valve disease Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
239000003906 humectant Substances 0.000 description 1
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
HBDSHCUSXQATPO-BGBJRWHRSA-N indirubin-3'-monoxime Chemical compound O=C/1NC2=CC=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 HBDSHCUSXQATPO-BGBJRWHRSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000022760 infectious otitis media Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000004041 inotropic agent Substances 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
102000048260 kappa Opioid Receptors Human genes 0.000 description 1
230000004140 ketosis Effects 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
201000009546 lung large cell carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000001656 lutein Substances 0.000 description 1
235000012680 lutein Nutrition 0.000 description 1
229960005375 lutein Drugs 0.000 description 1
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
229960004999 lycopene Drugs 0.000 description 1
235000012661 lycopene Nutrition 0.000 description 1
239000001751 lycopene Substances 0.000 description 1
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229960003987 melatonin Drugs 0.000 description 1
DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
JYXPWUYLZPYOAH-UHFFFAOYSA-N methylhydrazine Chemical compound CN=N JYXPWUYLZPYOAH-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000020786 mineral supplement Nutrition 0.000 description 1
229940029985 mineral supplement Drugs 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
102000051367 mu Opioid Receptors Human genes 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
206010033072 otitis externa Diseases 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
201000008743 palmoplantar keratosis Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000000734 parasympathomimetic agent Substances 0.000 description 1
230000001499 parasympathomimetic effect Effects 0.000 description 1
229940005542 parasympathomimetics Drugs 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
238000003921 particle size analysis Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical compound NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
208000006155 precocious puberty Diseases 0.000 description 1
208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000011610 primary hypophysitis Diseases 0.000 description 1
239000006041 probiotic Substances 0.000 description 1
235000018291 probiotics Nutrition 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
230000010076 replication Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
201000006845 reticulosarcoma Diseases 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
239000000523 sample Substances 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000003195 sodium channel blocking agent Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
LHYPLJGBYPAQAK-UHFFFAOYSA-M sodium;pentanoate Chemical compound [Na+].CCCCC([O-])=O LHYPLJGBYPAQAK-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003890 substance P antagonist Substances 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
201000005882 tinea unguium Diseases 0.000 description 1
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
201000010044 viral meningitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1
235000020795 whole food diet Nutrition 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
108020001588 κ-opioid receptors Proteins 0.000 description 1
108020001612 μ-opioid receptors Proteins 0.000 description 1